Obesity and Hypothyroxinemia Together Heighten Risk of LGA Births in Pregnant Women: Study Finds
China: A recent Chinese cohort study published in Reproductive Biology and Endocrinology has found that maternal obesity and isolated maternal hypothyroxinemia (IMH) in late pregnancy significantly increase the risk of large-for-gestational-age (LGA) births. IMH, defined by low free thyroxine (FT4) with normal thyroid-stimulating hormone (TSH) levels, independently raised LGA risk by 1.3 times.
Obesity alone was linked to a nearly sixfold higher LGA risk and a sevenfold increase in IMH. Notably, women with both conditions had a 7.6-fold greater risk of delivering LGA newborns, indicating a strong synergistic effect. The findings highlight the importance of monitoring BMI and thyroid function during pregnancy.
The combined impact of isolated maternal hypothyroxinemia and other contributing factors on fetal growth outcomes has not been well established. To address this gap, Bin Zhang, Nanjing Medical University, Changzhou, China, and colleagues aimed to investigate whether the presence of IMH in the third trimester—characterized by free thyroxine (FT4) levels below the 5th percentile and TSH levels within the normal range—along with elevated prenatal body mass index (BMI), jointly increases the risk of delivering large-for-gestational-age newborns.
For this purpose, the researchers conducted a retrospective analysis of 11,478 Chinese pregnant women, utilizing laboratory data, including thyroid hormone levels, routine biochemical tests, and hospitalization records from a specialized hospital.
The study led to the following findings:
- The prevalence of obesity (BMI ≥ 30 kg/m²) and isolated maternal hypothyroxinemia (IMH) among the study population was 20.1% and 4.5%, respectively.
- Obese women had a 6.96-fold higher risk of developing IMH compared to women with normal weight (BMI < 25 kg/m²).
- The risk of delivering large-for-gestational-age (LGA) newborns was 5.88 times higher in obese women than in those with normal weight.
- Women with IMH had a 1.32-fold increased risk of LGA births compared to euthyroid women.
- These associations remained consistent in sensitivity analyses conducted among women under 35, first-time mothers, and those without pregnancy complications.
- Women with both obesity and IMH had a 7.60-fold greater risk of delivering LGA newborns compared to euthyroid women with normal weight.
- There was a statistically significant interaction between BMI categories and IMH on the risk of LGA births.
- Subgroup analyses confirmed this interaction among younger women, those with multiple pregnancies, and those without pregnancy-related complications.
The researchers found that in the large cohort of Chinese pregnant women, both obesity and isolated maternal hypothyroxinemia (IMH) in late pregnancy were independently associated with an increased risk of delivering large-for-gestational-age newborns. Notably, the coexistence of these two conditions further amplified this risk.
"The findings emphasize the potential value of combining prenatal BMI assessment with thyroid hormone profiling to identify women at elevated risk for LGA births," the authors stated. They further noted, "If confirmed in future studies, this approach could have significant clinical and public health implications, particularly given the growing concern surrounding LGA-related health outcomes."
Reference:
Zhang, B., Xi, S., Zhan, Z. et al. Maternal obesity and the incidence of large-for-gestational-age newborns in isolated hypothyroxinemia pregnancies: a comparative cohort study. Reprod Biol Endocrinol 23, 60 (2025). https://doi.org/10.1186/s12958-025-01394-z
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.